LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma's Global Development Team. Beth-Anne's main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma's development of innovative dermatologic therapies to patients around the world. Christine Garrett's main responsibility will be to lead a new program management organization which will be key for LEO Pharma in order to strengthen the company's global drug development capabilities and help make innovation available to patients faster.
LEO Pharma's Global Development Team plays an important role in the execution of the company's 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.
Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma's Global Development Team. Beth-Anne's main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma's development of innovative dermatologic therapies to patients around the world. Christine Garrett's main responsibility will be to lead a new program management organization which will be key for LEO Pharma in order to strengthen the company's global drug development capabilities and help make innovation available to patients faster.
LEO Pharma's Global Development Team plays an important role in the execution of the company's 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of $1.6 billion.
